Expresión de TLR-9 en muestras de tejido con diagnóstico histopatológico de carcinoma escamoso de laringe del Hospital Central Militar
Contenido principal del artículo
Resumen
Determinar la expresión de TLR 9 en tejido con diagnóstico histopatológico de cáncer escamoso de laringe de pacientes del Hospital Central Militar.
Detalles del artículo
Sección
Cómo citar
Referencias
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword, Oncogene 2008; 27: 218-24.
JRR. Mueren 60 mil personas al año por cáncer en México. Excélsior. Periódico semanal 03 de febrero del 2008, año XCI-tomo I, Número 33,023México D.F.
DGE. Registro Histopatológico de las Neoplasias en México, 2007.
Myers E. Cancer of the head and neck. Editorial Saunders. 2003; 4a. Edición.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:
-8.
Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunological reviews 2007; 20: 82-101.
Huang B, Zhao J, Unkeless J, Feng ZH, Xiong H.: TLR signaling by tumor and immune cells: a double-edged sword. Review. Nature Oncogene
; 27: 218-24.
Cherfils-Vicini J, Cremer I. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010; 120(4): 1285-97.
Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008; 27: 161-7.
Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology 1989; 7: 145-73.
Takeshita F, Ishii KJ, Ueda A, Ishigatsubo Y, Klinman D. M. Positive and negative regulatory elements contribute to CpG oligonucleotidemediated regulation of human IL-6 gene expression. Eur J Immunol 2000; 30: 108-16.
Hacker H. et al. Immune cell activation by bacterial CpG-DNA through myeroid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF) 6. J Exp Med 2000; 192: 595-600.
Krieg CAM. Development of TLR-9 agonists for cancer therapy. Coley Pharmaceutical Group, Wellesley, Massachusetts, USA. J Clin Invest 2007; 117(5): 1184-94.
Peter M, Bode K, Lipford GB, Eberle F, Heeg K, Dalpke AH. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Department of Medical Microbiology and Hygiene, University Heidelberg, Heidelberg, Germany, and Coley Pharmaceutical Group, Inc., Wellesley, MA, USA. Immunology 2008; 123(1): 118-2.
Hernández AI, Martínez TL, Sánchez R, Mora I, Carrasco IG, Aragón FR. Expresión del receptor tipo toll 7 en muestras de tejido con diagnóstico histopatológico de carcinoma escamoso de laringe. Rev Sanid Milit Mex 2010; 64(1): 24-36.
Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005; 105: 489-95.